Document is current
Any future updates will be listed below
-
Authors
Bizzotto, Sara
Walsh, Christopher A. https://orcid.org/0000-0002-0156-2238
- License Information
-
More Information
Article History
Accepted: 11 February 2022
First Online: 23 March 2022
Competing interests
: C.A.W. is a paid consultant (cash and no equity) for Third Rock Ventures and is on the Clinical Advisory Board (cash and equity) of Maze Therapeutics. No research support was received. These companies did not fund and had no role in the writing of this Review. S.B. declares no competing interests.
